Who are Raltegravir and Atazanavir's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/raltegravir-and-atazanavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Raltegravir and Atazanavir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Raltegravir and Atazanavir (Raltegravir and Atazanavir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (integrase inhibitor + protease inhibitor). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (integrase inhibitor + protease inhibitor) HIV integrase and HIV protease Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Raltegravir and Atazanavir (Raltegravir and Atazanavir) — Peter J. Ruane, M.D., Inc.. This combination inhibits HIV replication by blocking integrase (raltegravir) and protease (atazanavir), preventing viral DNA integration and polyprotein processing.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Raltegravir and Atazanavir TARGET	Raltegravir and Atazanavir	Peter J. Ruane, M.D., Inc.	marketed	Antiretroviral combination (integrase inhibitor + protease inhibitor)	HIV integrase and HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (integrase inhibitor + protease inhibitor) class)

Peter J. Ruane, M.D., Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Raltegravir and Atazanavir — Competitive Intelligence Brief. https://druglandscape.com/ci/raltegravir-and-atazanavir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab